The supporting information for the original article provides detailed experimental data and results to support the findings of the study. The study investigates the effects of a mitochondrial metabolism blockade nano-adjuvant, TPP-TAM, on the immune-resistant microenvironment and its impact on albumin-bound paclitaxel-based chemo-immunotherapy. Key findings include: 1. **Chemical Synthesis and Characterization**: The chemical synthesis process of TAM-C6 and TPP-TAM is described, along with their 1H-NMR and HR-MS spectra. 2. **In Vitro Effects**: Western blot assays show that TPP-TAM@Alb treatment reduces the expression of PD-L1 and TGF-β proteins in 4T1 cells, indicating improved immune response. 3. **Cell Viability and Apoptosis**: The viability of 4T1 and MCF-7 cells treated with different concentrations of TAM, TPP-TAM, TPP-TAM@Alb, and PTX@Alb is evaluated, showing that TPP-TAM@Alb enhances cell death. 4. **ROS Generation and Fluorescence**: The generation of ROS and live cell fluorescence are assessed, demonstrating the therapeutic effects of TPP-TAM@Alb. 5. **Tumor Growth and Metastasis**: The growth of 4T1 tumors and the formation of lung metastases are monitored, showing that TPP-TAM@Alb effectively inhibits tumor growth and metastasis. 6. **Toxicity Assessment**: Histopathological images of organs from treated mice are provided, indicating no significant toxicity from TPP-TAM@Alb treatment. These results collectively support the potential of TPP-TAM@Alb as a promising nano-adjuvant for enhancing the efficacy of albumin-bound paclitaxel-based chemo-immunotherapy.The supporting information for the original article provides detailed experimental data and results to support the findings of the study. The study investigates the effects of a mitochondrial metabolism blockade nano-adjuvant, TPP-TAM, on the immune-resistant microenvironment and its impact on albumin-bound paclitaxel-based chemo-immunotherapy. Key findings include: 1. **Chemical Synthesis and Characterization**: The chemical synthesis process of TAM-C6 and TPP-TAM is described, along with their 1H-NMR and HR-MS spectra. 2. **In Vitro Effects**: Western blot assays show that TPP-TAM@Alb treatment reduces the expression of PD-L1 and TGF-β proteins in 4T1 cells, indicating improved immune response. 3. **Cell Viability and Apoptosis**: The viability of 4T1 and MCF-7 cells treated with different concentrations of TAM, TPP-TAM, TPP-TAM@Alb, and PTX@Alb is evaluated, showing that TPP-TAM@Alb enhances cell death. 4. **ROS Generation and Fluorescence**: The generation of ROS and live cell fluorescence are assessed, demonstrating the therapeutic effects of TPP-TAM@Alb. 5. **Tumor Growth and Metastasis**: The growth of 4T1 tumors and the formation of lung metastases are monitored, showing that TPP-TAM@Alb effectively inhibits tumor growth and metastasis. 6. **Toxicity Assessment**: Histopathological images of organs from treated mice are provided, indicating no significant toxicity from TPP-TAM@Alb treatment. These results collectively support the potential of TPP-TAM@Alb as a promising nano-adjuvant for enhancing the efficacy of albumin-bound paclitaxel-based chemo-immunotherapy.